Navigation Links
SIRO ClinPharm and Advanced Clinical Trial Solutions Ink Strategic Alliance
Date:4/17/2009

Alliance provides global oncology clinical development solutions in North America, Europe and India.

PRINCETON, N.J., April 17 /PRNewswire/ -- SIRO ClinPharm (SIRO), a leading multinational Contract Research Organization (CRO), today announced the signing of a strategic alliance with Advanced Clinical Trial Solutions LLC (ACT Solutions), Flemington, NJ, USA, a service provider in oncology drug development with a business concentration in North America. This alliance will enable SIRO to expand its oncology clinical development and patient recruitment expertise to North America. ACT Solutions and its clients will benefit by gaining access to SIRO's clinical study management, patient recruitment, data management, biostatistics and medical writing capabilities in India and European countries.

"We are delighted to add ACT Solution's North American expertise in our service offering to our customers, said Dr Chetan Tamhankar, COO of SIRO ClinPharm group. "This alliance is the first step for SIRO in creating delivery capabilities in North America."

"We are excited about aligning our strengths in oncology with SIRO's international delivery capabilities," said Patricia Devitt Risse, Pharm. D, President of ACT Solutions LLC. "This step addresses the changing dynamics of the clinical research sector. We remain committed to providing a level of expertise and service that built our reputation and loyal client base to this point and this alliance expands our ability to deliver capabilities in Europe and India," she explained.

According to Patricia Terek, President of SIRO ClinPharm, USA, "This step will help meet the growing needs of our oncology customers to have access to operational capabilities in North America. We are excited to offer the clinical development expertise of ACT Solutions in North America to our customers globally."

About SIRO

SIRO is a leading multinational contract research organization. With a presence in over 15 countries across North America, Europe and Asia, SIRO offers global bio-technology and pharmaceutical companies end to end clinical trial services. Established in year 1996, SIRO has emerged as a leading name for high speed and optimal cost of conducting clinical research. More information about the SIRO group is available at www.siroclinpharm.com

About Advanced Clinical Trial Solutions LLC

Advanced Clinical Trial Solutions LLC (ACT Solutions) is a privately held company that is devoted to operational excellence in global oncology drug development. ACT Solutions is staffed solely with experienced oncology personnel that has enabled it to grow its business annually and to establish strategic partnerships to expand the scope of the ACT Solutions service offerings. More information about ACT Solutions is available at www.actsolutions.org


'/>"/>
SOURCE SIRO ClinPharm
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
2. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
3. Advanced Life Sciences Announces Filing of Shelf Registration Statement
4. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
5. METTLER TOLEDO and AAPS: Utilization of Process Modeling and Advanced Process Control in QbD based Drug Development and Manufacturing
6. Roche to Introduce New LightCycler(R) MRSA Advanced Test in the EU
7. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
8. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
9. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
10. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
11. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Brain State ... via Kickstarter. The proceeds will be used to fund production of the company’s ... original Kickstarter goal by nearly 1,000%. , The B2v2 is the world’s first ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... colleague Dr. Justin Zalewsky in offering LANAP® and LAPIP™ laser treatments. Drs. Hoge ... True Regeneration™ to patients, a minimally invasive and less painful option that produces ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... ulcers is now being assessed in clinical trials in the United States. (clinicaltrials.gov ... to your nurse or physician or find your nearest participating clinic here ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of ... 27th. His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo ... West and discuss how probiotics have shown impressive data in areas outside the gut ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):